French healthcare group Sanofi (SASY.PA) is investing 350 million euros ($432.4 million) in a Canadian vaccine
facility, which the drugmaker said would help it meet growing demand in this area. Sanofi’s new investment will finance the construction of a new state-of-the-art vaccine manufacturing facility at the Sanofi Pasteur Canadian headquarters in Toronto, Ontario.
The new facility would allow its Sanofi Pasteur division to meet the growing demand of five-component acellular pertussis (5-acP) antigen, the company added.
Sanofi sealed two major takeovers at the start of 2018, buying hemophilia specialist Bioverativ for $11.6 billion and acquiring Ablynx, which is developing a prized experimental drug for a rare blood disorder, for 3.9 billion euros ($4.8 billion).
Related posts:
Experts express worry over Nigeria’s failing health sector
Church donates health centre to Odeda Community
Navy logistics command gives free treatment in Oghara
Healthcare: Persons living with disabilities seek inclusive budgetting
NAF provides free medical services to Osun residents
Matawalle launches free healthcare for 34,000 less privileged, vulnerable, others
CSOs seek stakeholders collaboration in healthcare reforms
LCCI, experts advise govt on improving healthcare for women
